Tapering Baclofen After Short-Course for Hiccups
For a 3-5 day course of baclofen 10 mg three times daily for intractable hiccups, tapering is generally not required—you can stop abruptly.
Rationale Based on Evidence
The FDA label clearly warns against abrupt withdrawal of baclofen and states "the dose should be reduced slowly when the drug is discontinued" 1. However, this warning applies primarily to patients at risk of physical dependence, which develops heterogeneously across patients but typically requires longer exposure.
Key Decision Points
Duration and dose matter critically:
- Physical dependence to GABA-ergic medications like baclofen can develop within weeks, but many patients taking low doses for less than a month are unlikely to be physically dependent 2
- Your patient received only 3-5 days of treatment at a low dose (30 mg/day total)
- The benzodiazepine tapering guidelines (which apply to similar GABA-ergic mechanisms) explicitly state that "many patients who have been taking BZDs for less than a month, particularly at low doses, are unlikely to be physically dependent and typically able to discontinue the medication without a taper" 2
Clinical trial evidence supports short-course safety:
- Multiple studies used baclofen 10 mg three times daily for 3-5 days for hiccups without reporting withdrawal symptoms upon discontinuation 3, 4
- In the stroke hiccup trial, patients received this exact regimen (10 mg TID for 5 days) with no documented withdrawal events 3
- The chemotherapy-induced hiccup study used 10 mg TID for 3 days with only 2 cases (4.44%) experiencing relapse after drug withdrawal—not withdrawal symptoms, but hiccup recurrence 4
Practical Approach
Simply stop the medication after 3-5 days if:
- The hiccups have resolved
- No history of alcohol use disorder or other substance dependence
- No concurrent use of other CNS depressants
- Patient has normal renal function
Consider a brief 2-3 day taper (reduce to 10 mg twice daily, then once daily) only if:
- Patient expresses anxiety about stopping
- History of withdrawal from other medications
- Concurrent high-dose opioid use
- Severe renal impairment (baclofen is renally excreted) 1
Important Caveats
Monitor for hiccup recurrence, not withdrawal: The 4.44% relapse rate in one study 4 represents return of hiccups, not baclofen withdrawal syndrome. If hiccups recur, this indicates inadequate treatment duration, not a need for tapering.
Distinguish from chronic use: The severe withdrawal syndromes described in the literature (seizures, hallucinations, delirium) occur with chronic use, particularly at high doses (≥300 mg/day) or with abrupt discontinuation after months of therapy 5. Your 3-5 day course at 30 mg/day falls far below this threshold.
Renal function matters: Because baclofen is primarily renally excreted, patients with significant renal impairment may have drug accumulation even after short courses 1. In such cases, consider extending observation rather than formal tapering.